Financial Year 2019 31 March 2020 Dr. Andreas Eckert CEO 1 - - PowerPoint PPT Presentation

▶
financial year 2019 31 march 2020 dr andreas eckert ceo 1
SMART_READER_LITE
LIVE PREVIEW

Financial Year 2019 31 March 2020 Dr. Andreas Eckert CEO 1 - - PowerPoint PPT Presentation

Apr 07, 2023 104 likes •459 views

Financial Year 2019 31 March 2020 Dr. Andreas Eckert CEO 1 Globally Globa lly Pos Positi itione oned Niche Niche Play Player er in I in Iso sotope tope Market Market Industrial Components Medical Devices Pharmaceuticals (

slide-1
SLIDE 1

1

Financial Year 2019

31 March 2020

  • Dr. Andreas Eckert

CEO

slide-2
SLIDE 2

2

Medical Devices (RADIATION THERAPY)

Implantats Applicators Devices

Raw materials/ API Projects/ API

Pharmaceuticals (RADIOPHARMA)

Devices

Globa Globally lly Pos Positi itione

  • ned

Niche Niche Play Player er in I in Iso sotope tope Market Market

Industrial Components (ISOTOPE PRODUCTS)

Products Services Trade Disposal 2019: approx. 180 Mio. Euro revenues

106 Mio. EUR 59% 30 Mio. EUR 17% 43 Mio. EUR 24%

Slides only for illustration – the spoken word shall be binding

Since 1st January 2020: MEDICAL

slide-3
SLIDE 3

>800 >800 Employ Employee ees (Head (Headco coun unts ts) ) 18 18 Site Sites s Wo World rldwide wide

3

Results 2019

(Mio. EUR)

Revenues 178,6 Net Income 22,0

Slides only for illustration – the spoken word shall be binding

47% 42% 9% 2%

EUROPE AMERICA ASIA MIDDLE EAST & AFRICA

slide-4
SLIDE 4

Rev Reven enue ues Incr Increa ease se 1992 1992-2019 2019

in Mio. EUR

4

  • incl. discontinued and continued operations

Slides only for illustration – the spoken word shall be binding

0,13 1 2 4 6 6 8 10 24 33 31 29 36 42 50 54 71 101 111 116 120 117 127 140 138 145 170 180 20 40 60 80 100 120 140 160 180 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

slide-5
SLIDE 5

Rev Reven enue ues Gro Grow by by 6% 6% to to 18 180 0 mm mm EUR EUR

5 Slides only for illustration – the spoken word shall be binding

2019 Total Revenues 178,6 Mio. EUR 2018 Total Revenues 168,7 Mio. EUR +6%

  • incl. discontinued and continued operations
  • 20,0

40,0 60,0 80,0 100,0 120,0 Isotope Products Radiation Therapy Radiopharma 2018 106,8 30,4 31,5 2019 105,9 30,1 42,7 In Mio. EUR

slide-6
SLIDE 6

Isot Isotop

  • pe Pro

e Produ duct cts s Rev Reven enue ue Gro Growth wth 201 2019, 9, in in Mio.

  • Mio. EUR

EUR

6 Slides only for illustration – the spoken word shall be binding

106,8

  • 4,4

+ 3,5 105,9

20 30 40 50 60 70 80 90 100 110 120 Revenues 2018 Organic Growtth Exchange Rate Effects Revenues 2019

Flat

slide-7
SLIDE 7

Rad Radioph iophar arma ma Rev Reven enue ue Gro Growth wth 20 2019 19, , in in Mio.

  • Mio. EUR

EUR

7 Slides only for illustration – the spoken word shall be binding

31,5 + 9,9 + 1,2 42,7

5 10 15 20 25 30 35 40 45 Revenues 2018 Organic Growtth Exchange Rate Effects Revenues 2019

Growing

slide-8
SLIDE 8

Rad Radiation iation The Thera rapy py Rev Reven enue ue Gro Growth wth 201 2019, 9, in in Mio.

  • Mio. EUR

EUR

8 Slides only for illustration – the spoken word shall be binding

30,4

  • 0,7

+ 0,5 30,1

5 10 15 20 25 30 Revenues 2018 Organic Growtth Exchange Rate Effects Revenues 2019

Flat

slide-9
SLIDE 9

9 Slides only for illustration – the spoken word shall be binding

Ne Net Inc t Incom

  • me

e – Dist Distrib ribut ution ion an and Gr d Growth wth FY 20 FY 2019 19

slide-10
SLIDE 10

Net Net I Inc ncome

  • me Gro

Grows ws by by 36 36% to 22 % to 22 mm mm EUR EUR

10

2019 Total Net Income 22,0 Mio. EUR +36% 2018 Total Net Income 16,1 Mio. EUR

Slides only for illustration – the spoken word shall be binding

0,0 2,0 4,0 6,0 8,0 10,0 12,0 14,0 Isotope Products Radiation Therapy Radiopharma 2018 11,6 0,7 6,4 2019 10,3 1,5 12,0 In Mio. EUR

slide-11
SLIDE 11

Net Net I Inc ncome

  • me Gro

Growth wth all all Seg Segmen ments ts in 201 in 2019, 9, in in Mio.

  • Mio. EUR

EUR

11 Slides only for illustration – the spoken word shall be binding

16,1

  • 1,2

+ 0,9 + 5,6 + 0,7 22,0

0,0 5,0 10,0 15,0 20,0 25,0 Net income 2018 Isotope Products Radiation Therapy Radiopharma Holding Net income 2019

The action is here

slide-12
SLIDE 12

Isot Isotop

  • pe Pro

e Produ duct cts s Net Net Inco Income me Gro Growth wth 201 2019, 9, in in Mio.

  • Mio. EUR

EUR

12 Slides only for illustration – the spoken word shall be binding

11,6 + 1,0

  • 0,3
  • 0,4

+ 0,1

  • 1,2

10,3

2 4 6 8 10 12 14 Net income 2018 Industry UWD Gamma Exchange Rate Effects Tax/Interest Net income 2019

Flat

slide-13
SLIDE 13

Rad Radioph iophar arma ma Net Net Inco Income me Gro Growth wth 201 2019, 9, in in Mio.

  • Mio. EUR

EUR

13 Slides only for illustration – the spoken word shall be binding

+ 6,4 + 11,2 + 2,1 + 0,0 + 1,0

  • 2,5

+ 12,0

2 4 6 8 10 12 14 16 18 20 Net income 2018 Revenues COGS Sales and Marketing Costs Administrative and Development Costs Exchange Rate/Interesrt/Tax Net income 2019

Growing

slide-14
SLIDE 14

Rad Radiation iation The Thera rapy py Net Net Inco Income me Gro Growth wth 201 2019, 9, in in Mio.

  • Mio. EUR

EUR

14 Slides only for illustration – the spoken word shall be binding

Flat

  • 0,5

0,7 0,6 0,1 0,0 0,5 + 0,1 1,5

0,0 0,2 0,4 0,6 0,8 1,0 1,2 1,4 1,6 Net income 2018 Revenues COGS Sales and Marketing Costs Administrative and Development Costs Exchange Rate/Interesrt/Tax Minorities Interest Net income 2019

slide-15
SLIDE 15

15 Slides only for illustration – the spoken word shall be binding

Cas Cashflo hflow and w and Balan Balance ce She Sheet et FY FY 20 2019 19

slide-16
SLIDE 16

Balan Balance ce She Sheet et as as of

  • f 31

31/12/2 /12/201 019, 9, in in Mio.

  • Mio. EUR

EUR

16

  • Cash at Hand 79 Mio. EUR
  • Debt Free
  • Equity Ratio 51%

Slides only for illustration – the spoken word shall be binding

Cash 79 Equity 138 Recievables 29 Minority Interests 1 Inventory 31 IFRS 16 Leasing 20 Intangible Assets 71 Accruals/Provisions 67 Fixed Assets 40 Other Short Term Payables 40 Others 23 Other Long Term Payables 7 Total Activ 274 Total Passiv 274

slide-17
SLIDE 17

Balan Balance ce She Sheet et Ext Exten ension sion ex exclus clusively ively du due to e to IFRS IFRS

Slides only for illustration – the spoken word shall be binding 17

Changes in Non-Current Assets, in mm EUR: No increase in balance sheet risks despite growth in 2019

slide-18
SLIDE 18

Ne Net L t Liqu iquidity idity

in Mio. EUR, year end

18

+10 mm EUR Share Buy-Back

Folie nur zur Illustration – es gilt das gesprochene Wort

2014 2015 2016 2017 2018 2019 Liquidity 22 31 37 58 54 79 Loan 19 16 12 2 Net Liquidity 3 15 25 56 54 79 10 20 30 40 50 60 70 80 10 20 30 40 50 60 70 80 In Mio. EUR

slide-19
SLIDE 19

Cas Cashflow i hflow in n 20 2019 19 in Mio. in Mio. EUR EUR

19 Slides only for illustration – the spoken word shall be binding

EBITDA: 44,2 Mio. EUR

54,2 39,9

  • 5,6
  • 10,0

0,5 78,9

0,0 10,0 20,0 30,0 40,0 50,0 60,0 70,0 80,0 90,0 100,0 Liquidity 31.12.18 CF Operating Activities CF Investing Activities CF Financing Activities Exchange Rate Effects Liquidity 31.12.19

Growth

slide-20
SLIDE 20

6,8 10,7 10,2 14,7 16,1 22,0

1,3 2,0 1,9 2,2 3,1 4,3

0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5 4,0 4,5 5,0 7,0 9,0 11,0 13,0 15,0 17,0 19,0 21,0 23,0 2014 2015 2016 2017 2018 2019 im Mio EUR/Aktie

Pr Profita

  • fitability

bility (Net (Net Inc Incom

  • me/ EP

e/ EPS) S)

20 Slides only for illustration – the spoken word shall be binding Industry& RI

Basis: 5,2 Mio. shares

slide-21
SLIDE 21

Sto Stock ck and and Dividen Dividend, d, in E in EUR/St UR/Stoc

  • ck

21 Slides only for illustration – the spoken word shall be binding

0,60 0,60 0,60 0,66 0,8 1,2 1,7

20 40 60 80 100 120 140 160 180 200 0,50 0,70 0,90 1,10 1,30 1,50 1,70 2014 2015 2016 2017 2018 2019 2020 Dividend in EUR/Share EUR/Aktie

slide-22
SLIDE 22

22

Impro Improve ved Pro Profi fita tabili bility ty Since Since 20 2014 14 Turn Turnar arou

  • und

nd

  • 2014

– Acquisition of Brazilian Isotope Specialist REM – Accreditation Gallium Generator/ API – New Management Board in Therapy Segment

  • 2015

– Sale of US-Seed Business to Theragenics – Closing of Oxford/ (US) – Profitable Sales of OPS to IPSEN

  • 2016

– Acquisition of Belgian Brachytherapie Unit – Acquisition of Brazilian Transports Specialist – FDA-Approval for NETSPOT/ (API of EZAG)

  • 2017

– Sale of Cyclotron Business to Alliance Medical – Acquisition of Gamma-Service Group, Leipzig

  • 2018

 Acquisition of WOMED  Merger BEBIG S.A. und EZAG AG

  • 2019 until today

 First Chinese bridgeheads established  Lutetium Production started  Profitable Sale of Production Site in Seneffe, Belgium  Attractive Development Pipeline

Slides only for illustration – the spoken word shall be binding

slide-23
SLIDE 23

Firs First Mil t Miles esto tone nes s Ach Achieve ieved in C in China hina

Slides only for illustration – the spoken word shall be binding 23

Eckert & Ziegler has formed a joint venture with TCL Health Care for the distribution of tumor irradiation devices in China

slide-24
SLIDE 24

Further Further Mi Milestone estone Achi Achieved: eved: Con Contr trac act t with CNRT with CNRT End End of July

  • f July

24

Transfer of Technology (1 - 3 years)

  • EZAG duplicates German

production plant in Chengdu for CNRT turnkey.

  • Scope:
  • Building a production line of

hot cells

  • Delivery of the inside

fittings

  • Training and instruction of

the Chinese on site

  • Stock of Sr-90

Joint Yttrium-Production (15 years)

  • As soon as the line in

Chengdu is running, the surplus production will be sold for joint account (50/50).

  • CNRT: responsible for the

production, provides the building and the production team.

  • EZAG: responsible for

distribution, supplies processed Sr-90 raw material and various consumables.

  • Own consumption of CNRT

at Y-90 is billed separately

Slides for Illustration – The spoken word shall be binding

slide-25
SLIDE 25

Our Our Str Strat ateg egy y for ac for active tive ph phar armac maceu eutica tical l ingr ingred edient ients

Germany Building Worldwide Supply Chains / Global Network

Status as of March 2020 Lutetium-177

  • Validated technology
  • Value chain has been completed
  • Five reactors qualified

thereof two non-European sites

  • First deliveries to customers

Status as of March 2020 Yttrium-90

  • New production site in

Boston initiated

  • Production site in Chengdu

Chengdu on schedule

  • Numerous alliances in the

pipeline

slide-26
SLIDE 26

26

OUTL OUTLOOK/ OOK/ Ex Expe pect ctat ation ions s for for 20 2020 20

Folie nur zur Illustration – es gilt das gesprochene Wort

slide-27
SLIDE 27

Key Key Elemen Elements ts of

  • f

Guida Guidanc nce 20 2020 20 (EBIT) (EBIT)

Slides only for illustration –the spoken word shall be binding 27

in Mio. EUR

slide-28
SLIDE 28

Cor Coron

  • na

a

  • Recommendations of various National Authorities implemented

– Standard hygiene measures and home work – Teams isolated from each other in time and place as far as possible

  • Californian production sites explicitly excluded from general closure edict

– EZAG in general seen as part of critical infrastructure (healthcare, nuclear)

  • Visible effects so far

– In some fields, declining orders:

  • Hospitals are shifting the focus from oncology to intensive care
  • Worldwide closures of scientific institutions lead to less re-orders of calibration sources

– Travel Restrictions

  • Technicians cannot provide maintenance and other travel-intensive services

– Transportation more difficult, because there are almost no commercial passenger flights – Absence of single parent employees

  • Counter measures

– Use of “Kurzarbeit”, where applicable (with 100% coverage) – Switch to cargo flights or other alternatives – Provisions / conservative earnings planning

  • Main risk

– Loss of production teams due to quarantine orders – Spreading recessionary effects

Slides only for illustration – the spoken word shall be binding 28

slide-29
SLIDE 29

Oil Oil Price Price

Slides only for illustration – the spoken word shall be binding 29

11.6 6.8 10.3 Profit contributions (Net Profit) of the Industry segment in EUR million, Shale Gas Exploration will collapse

slide-30
SLIDE 30

Add Additiona itional l Dev Develop elopmen ment t Exp Expen ense ses (at at eq equit uity), ), 3-4 mm 4 mm EUR EUR/a /a

PentixaFor: Diagnosis │ 68Ga

  • Design of a clinical study:

Phase II; 50 patients

  • Indication: indolent Lymphoma
  • Incidences per year: 79.000 USA & EU
  • Average life expectancy: 12 -15 years
  • Primary end point: identical to 18FDG,
  • r better
  • Review of a Phase III clinical study, after

successful meta-analysis of published clinical studies

PentixaTher: Therapy │ 90Y

  • Design of a clinical study:

Phase I; 10 patients

  • Indication: ZNS-Lymphome
  • Incidences per year: 20.000 worldwide
  • Average life expectancy: 12-18 months
  • Primary end point: Tolerance and dosage

finding

  • Treatment: Combination of Methotrexat,

Rituximab (anti-CD20 antibody) and/or irradiation

  • Reimbursement Rituximab: ~100.000 EUR/a

68Ga 90Y

slide-31
SLIDE 31

Mor Morning ning-Afte After-Pill Pill for Irra for Irradiat diation ion Relat Related ed Myelosu Myelosupp ppre ression ssion

Slides only for illustration – the spoken word shall be binding 31

  • Excellent safety profile
  • High tolerance
  • Can be taken orally
  • Orphan Drug status

received by EMA und FDA

  • Clinical evaluation in

preparation

slide-32
SLIDE 32

Gro Growth wth Path Path 20 2020 20 Rema Remains ins Solid Solid

Theranostics / Precision Oncology

  • Stable demand for

Gallium-68

  • First delivery of Lu-

177 started

  • Several clinical trials

with PSMA in final stage

Slides only for illustration – the spoken word shall be binding 32

Radioembolisation / Liver Carcinoma

  • Increasing demand

for Yttrium-90

  • Additional US

production site initiated

  • Built-up of Y-90 plant

in Chengdu right on schedule Pipeline

  • Acquisition of additional

pharma alliances

  • Follow-up orders for existing

cooperations signed

  • Unbroken interest in

radiopharmaceuticals

  • Positive news flow expected
slide-33
SLIDE 33

Thank Thank you! you!

Folie nur zur Illustration – es gilt das gesprochene Wort 33

slide-34
SLIDE 34

Fina Financ ncial ial Calen Calenda dar r / I / IR Con R Conta tact ct

IR Contact Eckert & Ziegler AG Karolin Riehle Investor Relations & PR Robert-Rössle-Str. 10 D-13125 Berlin

  • Tel. +49 30 94 10 84-138

Fax +49 30 94 10 84-112 karolin.riehle@ezag.de www.ezag.de ISIN DE0005659700 Reuters EUZ.DE

34 Folie nur zur Illustration – es gilt das gesprochene Wort

31.03.2020 Publication FY 2019 12.05.2020 Quarterly Report I 17.06.2020 Annual General Meeting June 2020 Spring Conference in Frankfurt 13.08.2020 Quarterly Report II 10.11.2020 Quarterly Report III

(subject to changes)